MA53809A - Composés bifonctionnels comprenant des peptides d'insuline et des peptides d'egf(a) - Google Patents

Composés bifonctionnels comprenant des peptides d'insuline et des peptides d'egf(a)

Info

Publication number
MA53809A
MA53809A MA053809A MA53809A MA53809A MA 53809 A MA53809 A MA 53809A MA 053809 A MA053809 A MA 053809A MA 53809 A MA53809 A MA 53809A MA 53809 A MA53809 A MA 53809A
Authority
MA
Morocco
Prior art keywords
peptides
egf
compounds including
bifunctional compounds
including insulin
Prior art date
Application number
MA053809A
Other languages
English (en)
Inventor
Claudia Ulrich Hjørringgaard
Susanne Hostrup
Thomas Børglum Kjeldsen
Peter Madsen
Martin Werner Borchsenius Münzel
Mathias Norrman
Gro Klitgaard Povlsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA53809A publication Critical patent/MA53809A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA053809A 2018-10-05 2019-10-04 Composés bifonctionnels comprenant des peptides d'insuline et des peptides d'egf(a) MA53809A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18198892 2018-10-05

Publications (1)

Publication Number Publication Date
MA53809A true MA53809A (fr) 2022-01-12

Family

ID=64017248

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053809A MA53809A (fr) 2018-10-05 2019-10-04 Composés bifonctionnels comprenant des peptides d'insuline et des peptides d'egf(a)

Country Status (8)

Country Link
US (1) US11649269B2 (fr)
EP (1) EP3861017A1 (fr)
JP (1) JP7434299B2 (fr)
CN (1) CN112789289A (fr)
AR (1) AR116605A1 (fr)
MA (1) MA53809A (fr)
TW (1) TW202028229A (fr)
WO (1) WO2020070276A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7170332B2 (ja) 2016-12-09 2022-11-14 アクストン バイオサイエンシズ コーポレーション インスリンとｆｃの融合物および使用方法
HUE065725T2 (hu) 2018-06-29 2024-06-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és alkalmazási eljárások
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
HRP20231433T1 (hr) 2019-12-19 2024-03-29 Akston Biosciences Corporation Inzulin-fc fuzijski proteini ultradugog djelovanja i načini uporabe
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
HUE062716T2 (hu) 2020-04-10 2023-11-28 Akston Biosciences Corp Antigénspecifikus immunterápia COVID-19 fúziós fehérjékhez és az alkalmazási eljárások
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CA3193453A1 (fr) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Conjugues polypeptidiques et leurs procedes d'utilisation
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
JP2025512832A (ja) 2022-03-30 2025-04-22 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド ポリペプチドコンジュゲートの液体医薬組成物およびその使用の方法
CN115947822B (zh) * 2022-07-04 2023-08-18 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其药物组合物和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101784563B (zh) 2007-08-15 2015-02-04 诺沃-诺迪斯克有限公司 具有包括含亚烷基二醇的氨基酸的重复单位的酰基部分的胰岛素
PL2910570T3 (pl) 2008-03-18 2017-06-30 Novo Nordisk A/S Stabilizowane względem proteaz, acylowane analogi insuliny
AU2009238550B2 (en) 2008-04-23 2014-11-27 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 ( PCSK9) variants and uses thereof
GB201005005D0 (en) * 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
RU2014101501A (ru) 2011-06-20 2015-07-27 Дженентек, Инк. Связывающие pcsk9 полипептиды и способы применения
KR20160124787A (ko) 2014-02-21 2016-10-28 메디뮨 엘엘씨 항-pcsk9∼glp-1 융합체 및 사용 방법
CN104558199B (zh) 2014-09-05 2018-07-06 成都康弘生物科技有限公司 一种治疗高胆固醇血症的融合蛋白制备及其用途
WO2016164762A1 (fr) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucléotides codant pour des mutants, au niveau des domaines egf-a et intracellulaire, du récepteur des lipoprotéines basse densité et et leurs procédés d'utilisation
KR20180038049A (ko) 2015-08-25 2018-04-13 노보 노르디스크 에이/에스 신규한 인슐린 유도체 및 그것의 의학적 사용
RU2747877C2 (ru) 2016-01-13 2021-05-17 Ново Нордиск А/С Аналоги эфр(а) с заместителями - жирными кислотами

Also Published As

Publication number Publication date
CN112789289A (zh) 2021-05-11
WO2020070276A1 (fr) 2020-04-09
TW202028229A (zh) 2020-08-01
US11649269B2 (en) 2023-05-16
AR116605A1 (es) 2021-05-26
EP3861017A1 (fr) 2021-08-11
JP2022504153A (ja) 2022-01-13
JP7434299B2 (ja) 2024-02-20
US20220009989A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
MA53809A (fr) Composés bifonctionnels comprenant des peptides d'insuline et des peptides d'egf(a)
EP4086280A4 (fr) Dérivé d'insuline
EP3925652A4 (fr) Aiguille d'insuline sûre
EP3876770A4 (fr) Dispositif vaporisateur comprenant plus d'un élément chauffant
EP3794397A4 (fr) Affichage proche de l'& x152;il comprenant des ensembles projecteurs se chevauchant
EP3823543A4 (fr) Applicateur et cartouche d'agrafes
EP3694582A4 (fr) Dispositif d'injection à un ensemble adhésif
EP3870257A4 (fr) Accouplement d'unités de cartouche
EP3902564A4 (fr) Variants d'igg fc à usage vétérinaire
EP3731569A4 (fr) Équipement d'utilisateur
IL279901A (en) Antibodies comprising a polypeptide inserted in framework 3 region
GB201803990D0 (en) Joint d'etancheite air-feu et assemblage comprenant un tel joint
EP3918854A4 (fr) Position d'équipement utilisateur
EP3836702A4 (fr) Équipement d'utilisateur
EP3754750A4 (fr) Dispositif d'aération
EP3662292A4 (fr) Cartouche d'analyseur à balai capillaire
EP3820055A4 (fr) Terminal d'utilisateur
EP3866622A4 (fr) Cartouche et dispositif de génération d'aérosol la comprenant
EP3920750A4 (fr) Fer à cheveux doté d'un dispositif de chauffage en céramique
EP3817259A4 (fr) Terminal d'utilisateur
EP3968970A4 (fr) Anesthésique local comprenant un modulateur de canaux à trp
EP3906373A4 (fr) Dispositif d'interface d'entrée modulaire à interaction multi-axiale
EP3918931A4 (fr) Inhalateur d'arôme
EP3832923A4 (fr) Terminal d'utilisateur
EP3817588A4 (fr) Atomiseur et cartouche le comprenant